BACKGROUND: Long non-coding RNAs (lncRNAs) are a subset of non-coding RNAs. Abnormal expression of lncRNAs is associated with the development of cancers including gastric cancer (GC). Increasing evidence in this field reveals that lncRNAs have a key role in biological actions via modulating the expression of genes at various genomic levels. BC032913, as a novel antisense lncRNA, may have a role in GC progression. OBJECTIVE: The very aim of this study was to examine the clinical significance and the functional role of lncRNA BC032913 in GC. METHODS: QRT-PCR technique was exerted to survey the expression level of BC032913 in GC tissues and matched adjacent non-tumorous tissues. Furthermore, the association between clinicopathological parameters and the expression level of BC032913 was evaluated. RESULTS: BC032913 expression was downregulated in cancerous tissues as compared with adjacent non-tumorous tissues (P = 0.0108). Downregulation of BC032913 expression did not demonstrate a significant association with clinicopathological parameters. CONCLUSION: LncRNA BC032913 may be considered as an impressive therapeutic target for GC.
BACKGROUND: Long non-coding RNAs (lncRNAs) are a subset of non-coding RNAs. Abnormal expression of lncRNAs is associated with the development of cancers including gastric cancer (GC). Increasing evidence in this field reveals that lncRNAs have a key role in biological actions via modulating the expression of genes at various genomic levels. BC032913, as a novel antisense lncRNA, may have a role in GC progression. OBJECTIVE: The very aim of this study was to examine the clinical significance and the functional role of lncRNA BC032913 in GC. METHODS: QRT-PCR technique was exerted to survey the expression level of BC032913 in GC tissues and matched adjacent non-tumorous tissues. Furthermore, the association between clinicopathological parameters and the expression level of BC032913 was evaluated. RESULTS: BC032913 expression was downregulated in cancerous tissues as compared with adjacent non-tumorous tissues (P = 0.0108). Downregulation of BC032913 expression did not demonstrate a significant association with clinicopathological parameters. CONCLUSION: LncRNA BC032913 may be considered as an impressive therapeutic target for GC.